Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib
Clinical trial NCT02314143 · TERMINATED
Trial details
- NCT number
- NCT02314143
- Sponsor
- GlaxoSmithKline
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-11-13
- Primary completion
- 2017-01-19
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.